000144973 001__ 144973
000144973 005__ 20240813150347.0
000144973 0247_ $$2doi$$a10.1016/bs.irn.2019.10.013
000144973 0247_ $$2pmid$$apmid:31779824
000144973 0247_ $$2ISSN$$a0074-7742
000144973 0247_ $$2ISSN$$a2162-5514
000144973 0247_ $$2altmetric$$aaltmetric:71416658
000144973 037__ $$aDZNE-2020-00337
000144973 041__ $$aEnglish
000144973 082__ $$a610
000144973 1001_ $$0P:(DE-HGF)0$$aGiagkou, Nikolaos$$b0
000144973 245__ $$aProgressive supranuclear palsy.
000144973 260__ $$aHeidelberg [u.a.]$$bElsevier, Acad. Press$$c2019
000144973 264_1 $$2Crossref$$3print$$bElsevier$$c2019-01-01
000144973 3367_ $$2DRIVER$$aarticle
000144973 3367_ $$2DataCite$$aOutput Types/Journal article
000144973 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1723554197_24566
000144973 3367_ $$2BibTeX$$aARTICLE
000144973 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000144973 3367_ $$00$$2EndNote$$aJournal Article
000144973 520__ $$aProgressive supranuclear palsy (PSP) is a neurodegenerative disease characterized pathologically by 4 repeat tau deposition in various cell types and anatomical regions. Richardson's syndrome (RS) is the initially described and one of the clinical phenotypes associated with PSP pathology, characterized by vertical supranuclear gaze paly in particular downwards, postural instability with early falls and subcortical frontal dementia. PSP can manifest as several other clinical phenotypes, including PSP-parkinsonism, -pure akinesia with gait freezing, -frontotemporal dementia, - corticobasal syndrome, - speech/language impairment. RS can also have a pathologic diagnosis other than PSP, including corticobasal degeneration, FTD-TDP-43 and others. New clinical diagnostic criteria take into account this phenotypic variability in an attempt to diagnose the disease earlier, given the current lack of a validated biomarker. At present, therapeutic options for PSP are symptomatic and insufficient. Recent large neuroprotective trials have failed to provide a positive clinical outcome, however, have led to the design of better studies that are ongoing and hold promise for a neuroprotective treatment for PSP.
000144973 536__ $$0G:(DE-HGF)POF3-344$$a344 - Clinical and Health Care Research (POF3-344)$$cPOF3-344$$fPOF III$$x0
000144973 542__ $$2Crossref$$i2019-01-01$$uhttps://www.elsevier.com/tdm/userlicense/1.0/
000144973 588__ $$aDataset connected to CrossRef Book Series, PubMed,
000144973 650_2 $$2MeSH$$aHumans
000144973 650_2 $$2MeSH$$aSupranuclear Palsy, Progressive: diagnosis
000144973 650_2 $$2MeSH$$aSupranuclear Palsy, Progressive: drug therapy
000144973 650_2 $$2MeSH$$aSupranuclear Palsy, Progressive: metabolism
000144973 650_2 $$2MeSH$$aSupranuclear Palsy, Progressive: physiopathology
000144973 7001_ $$0P:(DE-2719)2811373$$aHöglinger, Günter U$$b1$$udzne
000144973 7001_ $$0P:(DE-HGF)0$$aStamelou, Maria$$b2$$eCorresponding author
000144973 77318 $$2Crossref$$3book-chapter$$a10.1016/bs.irn.2019.10.013$$b : Elsevier, 2019-01-01$$p49-86$$tInternational Review of Neurobiology$$x0074-7742$$y2019
000144973 773__ $$0PERI:(DE-600)209876-3$$a10.1016/bs.irn.2019.10.013$$p49-86$$tInternational review of neurobiology$$v149$$x0074-7742$$y2019
000144973 8564_ $$uhttps://pub.dzne.de/record/144973/files/DZNE-2020-00337_Restricted.pdf
000144973 8564_ $$uhttps://pub.dzne.de/record/144973/files/DZNE-2020-00337_Restricted.pdf?subformat=pdfa$$xpdfa
000144973 909CO $$ooai:pub.dzne.de:144973$$pVDB
000144973 9101_ $$0I:(DE-588)1065079516$$6P:(DE-2719)2811373$$aDeutsches Zentrum für Neurodegenerative Erkrankungen$$b1$$kDZNE
000144973 9131_ $$0G:(DE-HGF)POF3-344$$1G:(DE-HGF)POF3-340$$2G:(DE-HGF)POF3-300$$3G:(DE-HGF)POF3$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lErkrankungen des Nervensystems$$vClinical and Health Care Research$$x0
000144973 9141_ $$y2019
000144973 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS
000144973 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline
000144973 915__ $$0StatID:(DE-HGF)0310$$2StatID$$aDBCoverage$$bNCBI Molecular Biology Database
000144973 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List
000144973 915__ $$0StatID:(DE-HGF)0110$$2StatID$$aWoS$$bScience Citation Index
000144973 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection
000144973 915__ $$0StatID:(DE-HGF)0111$$2StatID$$aWoS$$bScience Citation Index Expanded
000144973 915__ $$0StatID:(DE-HGF)1050$$2StatID$$aDBCoverage$$bBIOSIS Previews
000144973 915__ $$0StatID:(DE-HGF)1120$$2StatID$$aDBCoverage$$bBIOSIS Reviews Reports And Meetings
000144973 9201_ $$0I:(DE-2719)1110002$$kAG Höglinger 1 ; AG Höglinger$$lTranslational Neurodegeneration$$x0
000144973 980__ $$ajournal
000144973 980__ $$aVDB
000144973 980__ $$aI:(DE-2719)1110002
000144973 980__ $$aUNRESTRICTED